Sugi Predict

Sugi Predict / Compounds / SCHEMBL4792586

SCHEMBL4792586

SCHEMBL4792586

Cc1ccc(S(=O)(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.76
▸ ACHE P22303 2/20 0.62
▸ BCHE P06276 1/20 0.59
▸ KMT2A Q03164 4/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ RAPGEF4 Q8WZA2 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ HSD11B1 P28845 1/20 0.52
▸ PAX8 Q06710 1/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA3 P07451 1/20 0.50
▸ CA6 P23280 1/20 0.50
▸ CA5A P35218 1/20 0.50
▸ CA7 P43166 1/20 0.50
▸ CA9 Q16790 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27713190 0.94 GAA (0.67) GAAACHEBCHEKMT2AMEN1
SCHEMBL19599193 0.88 GAA (0.59) GAAACHEBCHEKMT2AMEN1
SCHEMBL12242119 0.88 GAA (0.59) GAAACHEBCHEKMT2AMEN1
SCHEMBL170033 0.87 GAA (1.00) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL4400955 0.87 GAA (1.00) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL10067072 0.87 GAA (1.00) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL4328574 0.87 HSD11B1 (0.55) GAAKMT2AMEN1ALDH1A1HSD11B1
SCHEMBL30072318 0.87 HSD11B1 (0.55) GAAKMT2AMEN1ALDH1A1HSD11B1
SCHEMBL79787 0.87 HSD11B1 (0.55) GAAKMT2AMEN1ALDH1A1HSD11B1
SCHEMBL2121770 0.87 HSD11B1 (0.55) GAAKMT2AMEN1ALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118580164-A Preparation method of sulfoxide derivative 华侨大学 2024-09-03 — — CN disclosed
US-11844274-B2 Organic electroluminescence device and compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2023-12-12 — — US disclosed
US-11844274-B2 Organic electroluminescence device and compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2023-12-12 — — US disclosed
US-20200321535-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2020-10-08 — — US disclosed
US-9855545-B2 Porous cyclodextrin polymeric materials and methods of making and using same CORNELL UNIVERSITY (US) 2018-01-02 — — US disclosed
WO-2017144393-A1 2-SUBSTITUTED 5-(PHENYL)-1,2-DIHYDRO-3H-3-BENZAZEPINE-3-CARBOXAMIDE DERIVATIVES AS BRD4 INHIBITORS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-31 — — WO disclosed
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS INTERVET INC. (US) 2017-07-13 — — US disclosed
US-20170173560-A1 POROUS CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME NATIONAL SCIENCE FOUNDATION 2017-06-22 — — US disclosed
US-9534086-B2 Methods of forming poly(aryl ether sulfone)s and articles therefrom INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2017-01-03 — — US disclosed
US-9309260-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2016-04-12 — — US disclosed
US-6444685-B1 THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS WYETH 2002-09-03 — — US disclosed
US-20020028797-A1 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION 2002-03-07 — — US disclosed
WO-2002006274-A1 N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 — — WO disclosed
US-6242654-B1 REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND MITSUI CHEMICALS, INC. (JP) 2001-06-05 — — US disclosed
EP-1013629-A1 Preparation process of fluorine subsituted aromatic compound Mitsui Chemicals, Inc. (JP) 2000-06-28 — — EP disclosed
US-5650548-A Olefin oligomerization process AMOCO CORPORATION (US) 1997-07-22 — — US disclosed
EP-0776319-A1 OLEFIN OLIGOMERIZATION PROCESS AMOCO CORPORATION (US) 1997-06-04 — — EP disclosed
WO-1997000232-A1 OLEFIN OLIGOMERIZATION PROCESS AMOCO CORPORATION (US) 1997-01-03 — — WO disclosed
US-4554381-A BORON TRIFLUORIDE, HYDROFLUORIC ACID RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1985-11-19 — — US disclosed
US-3970679-A Process for the production of organotin halides in sulphones as reaction medium CIBA-GEIGY CORPORATION (US) 1976-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS MPO, DHODH, DHX35 GAA 2044/4885ACHE 75/4885BCHE 221/4885
US-20020028797-A1 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 GAA 2167/4885ACHE 2937/4885BCHE 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.